If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
14,456.00    -82.00 (-0.56%)
Bid:
14,470.00
Ask:
14,472.00
Spread: 2.00 (0.014%)
Market Cap: £224.19b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Form 8.5 (EPT/RI)

21 May 2014 11:52

RNS Number : 6959H
GoldmanSachs International
21 May 2014
 



 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

(GS) GOLDMAN SACHS INTERNATIONAL

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

ASTRAZENECA PLC

(d) Date dealing undertaken:

20 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

YES - disclosed previously for PFIZER INC

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

USD 0.25 ordinary

Purchases

1,872,0075,88215,000

43.0850 GBP478.3000 SEK72.2700 USD

41.8850 GBP468.0000 SEK72.2700 USD

USD 0.25 ordinary

Sales

1,431,1785,882

43.0850 GBP474.4000 SEK

41.9150 GBP469.0000 SEK

ADR

Purchases

50,000

72.4131 USD

72.3189 USD

ADR

Sales

50,000

72.3660 USD

72.3660 USD

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

USD 0.25 ordinary

CFD

Opening a short position

1,000

42.0450 GBP

USD 0.25 ordinary

CFD

Opening a long position

15,000

42.1389 GBP

USD 0.25 ordinary

CFD

Opening a short position

380

42.1500 GBP

USD 0.25 ordinary

CFD

Opening a short position

37,860

42.1576 GBP

USD 0.25 ordinary

CFD

Opening a short position

5,546

42.2479 GBP

USD 0.25 ordinary

CFD

Opening a short position

146,078

42.2479 GBP

USD 0.25 ordinary

CFD

Opening a long position

6,500

42.2695 GBP

USD 0.25 ordinary

CFD

Opening a long position

18,400

42.3325 GBP

USD 0.25 ordinary

CFD

Reducing a short position

7,180

42.6685 GBP

USD 0.25 ordinary

CFD

Opening a short position

125

42.6802 GBP

USD 0.25 ordinary

CFD

Reducing a short position

500

42.7204 GBP

USD 0.25 ordinary

CFD

Reducing a short position

12,500

42.8083 GBP

USD 0.25 ordinary

CFD

Opening a short position

12,500

42.8349 GBP

USD 0.25 ordinary

CFD

Opening a short position

7,180

42.8445 GBP

USD 0.25 ordinary

CFD

Reducing a short position

2,000

42.8550 GBP

USD 0.25 ordinary

CFD

Reducing a short position

14,394

42.8554 GBP

USD 0.25 ordinary

CFD

Reducing a short position

6,780

42.8554 GBP

USD 0.25 ordinary

CFD

Reducing a short position

3,826

42.8554 GBP

USD 0.25 ordinary

CFD

Reducing a long position

3,984

42.9066 GBP

USD 0.25 ordinary

CFD

Opening a short position

50,000

43.0461 GBP

USD 0.25 ordinary

CFD

Opening a long position

10,000

43.0850 GBP

USD 0.25 ordinary

CFD

Reducing a short position

380

43.0850 GBP

USD 0.25 ordinary

CFD

Opening a short position

15,000

72.2700 USD

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

ADR

Call Option / (1.00 : 100.00)

Purchasing

750 (75,000)

77.5000 USD

AMERICAN

19/07/2014

2.4200 USD

ADR

Call Option / (1.00 : 100.00)

Selling

750 (75,000)

72.5000 USD

AMERICAN

19/07/2014

4.1200 USD

ADR

Put Option / (1.00 : 100.00)

Purchasing

39 (3,900)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

ADR

Put Option / (1.00 : 100.00)

Purchasing

11 (1,100)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

ADR

Put Option / (1.00 : 100.00)

Selling

11 (1,100)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

ADR

Put Option / (1.00 : 100.00)

Selling

39 (3,900)

60.0000 USD

AMERICAN

18/10/2014

1.0500 USD

USD 0.25 ordinary

Call Option / (1.00 : 1,000.00)

Selling

300 (300,000)

46.0000 GBP

AMERICAN

19/09/2014

1.8700 GBP

USD 0.25 ordinary

Call Option / (1.00 : 1,000.00)

Selling

300 (300,000)

46.0000 GBP

AMERICAN

19/09/2014

1.8700 GBP

USD 0.25 ordinary

Call Option / (1.00 : 1,000.00)

Selling

300 (300,000)

46.0000 GBP

AMERICAN

19/09/2014

1.8700 GBP

USD 0.25 ordinary

Put Option / (1.00 : 1,000.00)

Purchasing

300 (300,000)

40.0000 GBP

AMERICAN

19/09/2014

2.0000 GBP

USD 0.25 ordinary

Put Option / (1.00 : 1,000.00)

Purchasing

300 (300,000)

40.0000 GBP

AMERICAN

19/09/2014

2.0000 GBP

USD 0.25 ordinary

Put Option / (1.00 : 1,000.00)

Purchasing

300 (300,000)

40.0000 GBP

AMERICAN

19/09/2014

2.0000 GBP

 

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

21 May 2014

Contact name:

Aadithya Rao and Yiannis Bardis

Telephone number:

+44(20) 7051 9046 / +44(20) 7774 7107

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDUBUDBGSB
Date   Source Headline
29th Jul 20257:00 amRNSH1 and Q2 2025 results
24th Jul 20257:00 amRNSGefurulimab nanobody met Phase III endpoints
22nd Jul 20257:00 amRNSAstraZeneca plans to invest $50bn in the US
16th Jul 20257:00 amRNSUpdate on anselamimab in AL amyloidosis
14th Jul 20257:00 amRNSBaxdrostat met primary endpt in BaxHTN PhIII trial
4th Jul 20257:00 amRNSImfinzi approved in the EU for bladder cancer
1st Jul 20253:00 pmRNSTotal Voting Rights
24th Jun 20257:00 amRNSDatroway approved in US for EGFRm lung cancer
17th Jun 202511:45 amRNSHolding(s) in Company
13th Jun 20259:30 amRNSAstraZeneca enters into collaboration with CSPC
12th Jun 20253:00 pmRNSDirector/PDMR Shareholding
6th Jun 20257:00 amRNSFixed-duration Calquence approved in EU for 1L CLL
2nd Jun 20253:05 pmRNSBlock listing Interim Review
2nd Jun 20253:00 pmRNSTotal Voting Rights
27th May 20257:00 amRNSImfinzi recommended in EU for bladder cancer
23rd May 202510:00 amRNSDirector/PDMR Shareholding
21st May 20251:45 pmRNSDirector Declaration
20th May 20257:00 amRNSAcquisition of EsoBiotec completed
9th May 20257:00 amRNSImfinzi improved DFS in early bladder cancer
7th May 20257:30 amRNSEnhertu improved pCR in early-stage breast cancer
6th May 20257:00 amRNSCalquence combination approved in EU for 1L MCL
2nd May 20257:00 amRNSBreztri met primary endpoints in Ph3 asthma trials
1st May 20254:00 pmRNSDirector/PDMR Shareholding
1st May 20253:00 pmRNSTotal Voting Rights
29th Apr 20257:10 amRNSFixed-duration Calquence recommended in EU for CLL
29th Apr 20257:05 amRNSUpdate on CAPItello-280 Phase III trial
29th Apr 20257:00 amRNS1st Quarter Results
22nd Apr 20257:00 amRNSEnhertu combination improved PFS in 1L HER2+ mBC
11th Apr 20255:30 pmRNSResult of AGM
4th Apr 20257:05 amRNSImfinzi approved in EU for AEGEAN
4th Apr 20257:00 amRNSEnhertu approved in EU in post-ET breast cancer
1st Apr 20253:00 pmRNSTotal Voting Rights
31st Mar 20257:05 amRNSCalquence recommended for EU approval in 1L MCL
31st Mar 20257:00 amRNSImfinzi approved in the US for bladder cancer
21st Mar 202510:58 amRNSAZN invests $2.5bn in Beijing R&D & manufacturing
17th Mar 20257:10 amRNSEneboparatide Phase III trial met primary endpoint
17th Mar 20257:05 amRNSImfinzi approved in EU for limited-stage SCLC
17th Mar 20257:00 amRNSAstraZeneca to acquire EsoBiotec
12th Mar 20256:00 pmRNSHolding(s) in Company
7th Mar 20253:00 pmRNSDirector/PDMR Shareholding
7th Mar 202511:00 amRNSNotice of AGM
7th Mar 20257:00 amRNSImfinzi improved EFS in early-stage gastric cancer
6th Mar 20253:00 pmRNSDirector/PDMR Shareholding
5th Mar 20253:00 pmRNSDirector/PDMR Shareholding
3rd Mar 20253:00 pmRNSTotal Voting Rights
3rd Mar 20257:00 amRNSImfinzi recommended for EU approval for AEGEAN
28th Feb 20251:00 pmRNSEnhertu recommended in EU in post-ET breast cancer
26th Feb 20257:00 amRNSCamizestrant improved PFS in 1L HR+ breast cancer
19th Feb 20257:00 amRNSFiling of Form 20-F with SEC
18th Feb 20252:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.